Academic Journal

Pheophorbide a and paclitaxel bioresponsive nanoparticles as double-punch platform for cancer therapy

التفاصيل البيبلوغرافية
العنوان: Pheophorbide a and paclitaxel bioresponsive nanoparticles as double-punch platform for cancer therapy
المؤلفون: Moret F., Menilli L., Battan M., Tedesco D., Columbaro M., Guerrini A., Avancini G., Ferroni C., Varchi G.
المساهمون: Moret, F., Menilli, L., Battan, M., Tedesco, D., Columbaro, M., Guerrini, A., Avancini, G., Ferroni, C., Varchi, G.
بيانات النشر: MDPI
سنة النشر: 2021
المجموعة: Padua Research Archive (IRIS - Università degli Studi di Padova)
مصطلحات موضوعية: Nanoparticle, Paclitaxel, Pheophorbide A, Photodynamic therapy, Prodrug, Tumor microenvironment
الوصف: Cancer therapy is still a challenging issue. To address this, the combination of anticancer drugs with other therapeutic modalities, such as light-triggered therapies, has emerged as a promising approach, primarily when both active ingredients are provided within a single nanosystem. Herein, we describe the unprecedented preparation of tumor microenvironment (TME) responsive nanoparticles exclusively composed of a paclitaxel (PTX) prodrug and the photosensitizer pheophorbide A (PheoA), e.g., PheoA@PTX2S. This system aimed to achieve both the TME-triggered and controlled release of PTX and the synergistic/additive effect by PheoAmediated photodynamic therapy. PheoA@PTX2S were produced in a simple one-pot process, exhibiting excellent reproducibility, stability, and the ability to load up to 100% PTX and 40% of PheoA. Exposure of PheoA@PTX2S nanoparticles to TME-mimicked environment provided fast disassembly compared to normal conditions, leading to PTX and PheoA release and consequently elevated cytotoxicity. Our data indicate that PheoA incorporation into nanoparticles prevents its aggregation, thus providing a greater extent of ROS and singlet oxygen production. Importantly, in SK-OV-3 cells, PheoA@PTX2S allowed a 30-fold PTX dose reduction and a 3-fold dose reduction of PheoA. Our data confirm that prodrug-based nanocarriers represent valuable and sustainable drug delivery systems, possibly reducing toxicity and expediting preclinical and clinical translation.
نوع الوثيقة: article in journal/newspaper
وصف الملف: ELETTRONICO
اللغة: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/34452091; info:eu-repo/semantics/altIdentifier/wos/WOS:000690205400001; volume:13; issue:8; firstpage:1130; journal:PHARMACEUTICS; http://hdl.handle.net/11577/3399807; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85112668194
DOI: 10.3390/pharmaceutics13081130
الاتاحة: http://hdl.handle.net/11577/3399807
https://doi.org/10.3390/pharmaceutics13081130
رقم الانضمام: edsbas.65E822F1
قاعدة البيانات: BASE
الوصف
DOI:10.3390/pharmaceutics13081130